Delaware SBDC client Lisen Imprinting Diagnostic, Inc. (LisenID) has entered a know-how agreement with Mayo Clinic to research and develop innovative early cancer diagnostic solutions. This collaboration combines LisenID’s epigenetic imprinting technology with Mayo Clinic’s clinical expertise to address gaps in early cancer detection.

LisenID specializes in Quantitative Chromogenic Imprinted Gene In-Situ Hybridization (QCIGISH), a technology that can detect cancer at its inception by identifying epigenetic imprinting biomarker abnormalities. Unlike traditional genetic mutation-based diagnostics, QCIGISH enables highly sensitive and specific cancer detection at an earlier stage, potentially improving patient outcomes and reducing unnecessary treatments.

Transforming Early Lung Cancer Diagnosis
The initial focus of the collaboration is the research and development of a QCIGISH-based laboratory-developed test (LDT) for early lung cancer detection using transbronchial needle aspiration (TBNA) samples. This test aims to provide a more accurate, objective, and clinically actionable tool for diagnosing malignancies in peripheral pulmonary lesions (PPLs), which remain challenging with current cytology-based methods.

“We are excited to collaborate with Mayo Clinic, a global leader in clinical research and patient care,” said Dr. Tina Cheng, the co-founder and tech inventor of LisenID. “LisenID has demonstrated over 95% sensitivity and 90% specificity¹  detecting various early-stage cancers, including lung, thyroid, and cervical and many more. This collaboration seeks to accelerate the clinical validation and eventual commercialization of our technology, ultimately improving early cancer diagnosis and patient care worldwide.”

Path to Market and Future Expansion
Following clinical validation, LisenID plan to introduce the new diagnostic test as an LDT, paving the way for further regulatory approval and broader market adoption.

About LisenID

Lisen Imprinting Diagnostic, Inc. (LisenID) is a leader in epigenetic imprinting biomarker-based cancer diagnostics. With research facilities and a clinical validation laboratory in Wilmington, Delaware, LisenID is developing a portfolio of early cancer detection solutions powered by its proprietary QCIGISH technology. The company’s innovative approach enhances diagnostic accuracy and enables earlier intervention for multiple cancer types, including lung thyroid, cervical, breast, bladder, and prostate cancers.

After many successes here in Delaware, including an EDGE Grant win in 2024, the Delaware SBDC team is excited to see a LisenID win a major collaboration with an industry leader like Mayo Clinic. We’re cheering on LisenID as they grow a successful business and make an impact on cancer diagnostics worldwide!